Study S003342

A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of BGM0504 Injection in Chinese Non-diabetes Participants with Overweight or Obese

ClinicalTrials.gov record

Registration

Registration: NCT06704581
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: RECRUITING
Enrollment: 620
Start: 2024-10-28
Primary completion: 2025-11-27
Lead sponsor: BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
Conditions: Overweight or Obesity
Interventions: DRUG:5 mg BGM0504 injection; DRUG:10 mg BGM0504 injection administered subcutaneously (SC) once a week; DRUG:15 mg BGM0504 injection; DRUG:BGM0504 placebo
Results posted: FALSE

Registered primary outcomes

Percent Change from Baseline in Body Weight [Baseline,Week 36]
Percentage of Participants Who Achieve≥5% Body Weight Reduction [Baseline,Week 36]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.